tradingkey.logo

PharmaCyte Biotech Inc

PMCB
View Detailed Chart

1.000USD

-0.050-4.90%
Close 08/01, 16:00ETQuotes delayed by 15 min
6.90MMarket Cap
1.08P/E TTM

PharmaCyte Biotech Inc

1.000

-0.050-4.90%
Intraday
1m
30m
1h
D
W
M
D

Today

-4.90%

5 Days

+4.71%

1 Month

-9.91%

6 Months

-36.71%

Year to Date

-36.31%

1 Year

-46.52%

View Detailed Chart

Agency Rating

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(9)
Neutral(3)
Buy(1)
Indicators
Sell(4)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.002
Sell
RSI(14)
43.141
Neutral
STOCH(KDJ)(9,3,3)
54.497
Neutral
ATR(14)
0.068
High Vlolatility
CCI(14)
-36.783
Neutral
Williams %R
75.000
Sell
TRIX(12,20)
-0.342
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
1.017
Sell
MA10
0.993
Buy
MA20
1.040
Sell
MA50
1.051
Sell
MA100
1.165
Sell
MA200
1.426
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Ticker SymbolPMCB
CompanyPharmaCyte Biotech Inc
CEOMr. Joshua N. (Josh) Silverman
Websitehttps://pharmacyte.com/
KeyAI